Deutsche Bank announced on Friday that it had upgraded its advice on Roche from 'sell' to 'hold', while maintaining its price target of 215 Swiss francs on the stock.

Deutsche Bank, which had been 'sell' on the stock since January 2023, believes that the unfavorable market sentiment surrounding the stock could improve this year thanks to encouraging data in obesity.

In his view, the results unveiled yesterday for CT-388 are sufficiently interesting to embody a credible alternative to competing products from Novo Nordisk and Eli Lilly in a medium/long-term perspective.

According to DB, this factor could help offset more worrying factors, such as the recent failure of the clinical trial in myasthenia gravis, or the growing competition from HD Eylea (Regeneron) for sales of Vabysmo in diabetic macular edema.

Copyright (c) 2024 All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.